The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility


ÖZTEMÜR Z., ÖZTÜRK H., Circi E., BULUT O., ÜNER S., ALTUN A., ...More

HEALTHMED, vol.6, no.10, pp.3425-3429, 2012 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 6 Issue: 10
  • Publication Date: 2012
  • Journal Name: HEALTHMED
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, Veterinary Science Database
  • Page Numbers: pp.3425-3429
  • Keywords: Osteogenesis imperfecta, pamidronate, bone density, CHILDREN, ALENDRONATE, NERIDRONATE, CHILDHOOD
  • Sivas Cumhuriyet University Affiliated: Yes

Abstract

Objective: Osteogenesis imperfecta (OI) is a genetic disorder caused by the mutation in encoding collagen type I, and characterised by fragile bone and reduced bone mineral density. The purpose of this study was to analyse the effects siklik intravenous pamidronate treatment has on the bone mineral density and the fracture rateand mobility.